Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.39 |
| ▸ | UBE2M | P61081 | 4/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.36 |
| ▸ | SHH | Q15465 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796082 | 0.92 | KCNH2 (0.39) | KCNH2UBE2MDCUN1D1SHHSMO | |
| SCHEMBL2796662 | 0.91 | KCNH2 (0.49) | KCNH2SHHSMOKCNQ1CACNA1C | |
| SCHEMBL2797333 | 0.91 | UBE2M (0.38) | KCNH2UBE2MDCUN1D1SHHSMO | |
| SCHEMBL5046662 | 0.87 | KCNH2 (0.47) | KCNH2UBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2800189 | 0.82 | UBE2M (0.38) | UBE2MDCUN1D1SHHSMOTP53 | |
| SCHEMBL2800311 | 0.81 | UBE2M (0.40) | UBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2796258 | 0.81 | KCNH2 (0.45) | KCNH2UBE2MDCUN1D1TP53KCNQ1 | |
| SCHEMBL2796900 | 0.81 | UBE2M (0.36) | KCNH2UBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2800492 | 0.80 | KCNH2 (0.46) | KCNH2UBE2MDCUN1D1SHHSMO | |
| SCHEMBL4775988 | 0.80 | KCNH2 (0.51) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | KCNH2 578/4885UBE2M 2433/4885DCUN1D1 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.